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Abstract
Background: Approximately 180 million people worldwide, (3 % of the world’s population) are infected with hepatitis
C (HCV). Insulin resistance (IR) and type 2 diabetes (T2DM) are common extrahepatic manifestations of chronic HCV
infection and associated with poor treatment and liver-related outcomes. The presence of these metabolic complications
have been associated with poor response to interferon-based HCV antiviral therapy and increased risk of liver-related
outcomes. Metformin, an insulin sensitizer is known to improve HCV treatment response and has been associated with a
reduced risk of developing hepatocellular carcinoma (HCC). This study will evaluate the effect of metformin on preventing
progression or promoting regression of liver fibrosis, rate of virologic cure (SVR) and other metabolic measures in HCV-HIV
co-infected and HCV mono-infected study participants who have IR and are planning on initiating HCV treatment.
Methods: This study is a prospective 48-week single-centre, randomized, open-label, controlled trial of HIV-HCV
co-infected and HCV mono-infected patients with IR (HOMA-IR ≥ 2.0) who are planning to initiate HCV antiviral
therapy. Sixty participants will be recruited from The Ottawa Hospital Viral Hepatitis Clinic. Participants will be
randomized in a 1:1 ratio to either arm 1, metformin 2 g (1 g twice daily) plus lifestyle, or to arm 2, lifestyle alone.
The primary outcome will be the change in FibroScan® score (kPa) from baseline to week 12 (start of HCV treatment),
the end of HCV treatment (week 24) and 24 weeks post HCV treatment (week 48). Secondary outcomes include
changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures,
changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters.
Discussion: This pilot study will be the first to evaluate the role of metformin on liver fibrosis in HCV-HIV co-infected
and HCV mono-infected patients with IR receiving DAA HCV treatment. If metformin is effective in reducing liver
fibrosis in this patient population, this will represent a well-tolerated, easy-to-administer, inexpensive therapy that will
protect against negative HCV outcomes. This study will also be an opportunity to evaluate the impact of insulin
resistance and hyperglycemia on viral clearance in HCV-infected patients treated with interferon-free regimens.
Trial registration: ClinicalTrials.gov NCT02306070 version 4.0 (June 29, 2015)
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Background
Approximately 180 million people worldwide (3 % of the
world’s population) are infected with hepatitis C (HCV)
[1]. Although HCV mainly affects the liver, the virus is
also associated with several extrahepatic manifestations
including hematologic, autoimmune, dermatologic, and
endocrine disorders [2]. Insulin resistance (IR) and type
2 diabetes (T2DM) are the most common endocrine
disorders in HCV-infected individuals. This association
was first demonstrated in HCV-infected individuals with
cirrhosis compared with individuals with cirrhosis from
other causes (prevalence of T2DM 50 % versus 9 %,
respectively) [3]. HCV is believed to directly impact in-
sulin signaling by interacting with specific proteins such
as serine/threonine kinases that subsequently inhibit insu-
lin signaling molecules [4]. HCV is also believed to indir-
ectly cause insulin resistance by inducing the production
of pro-inflammatory cytokines that impair insulin signal-
ing pathways in uninfected tissues [5].
The presence of IR and T2DM in HCV has been associ-
ated with poor HCV antiviral treatment response [6–8],
acceleration of liver fibrosis [9, 10], increased risk for
hepatocellular carcinoma (HCC) [11], higher transplant
complication rates [12], and possibly increased morbidity
from cardiovascular and metabolic complications [13]. At
least one observational study identified improved IR in
genotype 1 HCV-infected patients achieving viral clear-
ance with HCV antiviral therapy [14].
Hepatic fibrosis is a response to liver injury that arises
from the activation of hepatic stellate cells (HSCs) by in-
flammatory cytokines. Once HSCs are activated, they
further release cytokines that promote inflammation,
fibrosis, contraction and mitosis [15]. Insulin resistance
is a major determinant of liver fibrosis, however, the
mechanism by which IR promotes liver fibrosis is not
well established.
In recent years, the treatment of HCV has evolved with
the development of direct-acting antiviral (DAA) therapies
(protease inhibitors, NS5a inhibitors, and nucleotide and
non-nucleotide polymerase inhibitors). Compared to inter-
feron and ribavarin therapies alone, these new treatments
are associated with significantly improved sustained
virological response (SVR) rates, shorter treatment dur-
ation and more favourable side effect profile.
The effect of DAA HCV treatments on insulin resistance
and long-term risk of type 2 diabetes has yet to be clearly
established. A randomized controlled trial of HCV mono-
infected study participants receiving 14 days of mono-
therapy with the protease inhibitor danoprevir, found
that serum HCV RNA and homeostatic model assess-
ment of insulin resistance (HOMA-IR) correlated sig-
nificantly (Spearman rho = 0.379, p < 0.0001) [16]. At
the end of 14 days of danoprevir monotherapy the
mean decrease in HCV RNA was 2.2 ± 1.3 log10 IU/ml
(p < 0.0001) in patients who received the active drug (n =
40), which correlated with a decrease in mean HOMA-IR
score by 1.6 ± 1.1 (p < 0.0001). In contrast, HCV-RNA and
HOMA-IR remained unchanged in placebo recipients.
The role of insulin resistance and hyperglycemia as pre-
dictors of SVR with DAA HCV treatment has not been
clearly established. There are also no studies to date that
have examined the role insulin resistance or hypergly-
cemia play in promoting progression or preventing regres-
sion of liver fibrosis in patients that have achieved SVR
with HCV antiviral therapy.
In high-risk populations, metformin, an insulin sensitizer,
has been shown to delay or prevent the onset of T2DM
[17]. While it is unknown whether this specific benefit ex-
tends to those infected with HCV, metformin does improve
HCV treatment and liver-related outcomes. At least one
study showed treatment with metformin resulted in higher
SVR rates when compared with the control group (59.2 %
vs. 38.8 %, chi-square 4.083, p = 0.043) [18]. HCV-infected
patients with cirrhosis and T2DM who were taking metfor-
min had a decreased risk of developing HCC [19, 20].
At the cellular level, metformin is highly concentrated
in the liver and improves IR through the activation of
AMP-activated protein kinase (AMPK) which decreases
gluconeogenesis in the liver and increases glucose uptake in
the skeletal muscle [21]. In vitro studies have demonstrated
that pharmacologic activation of AMPK with metformin
may have antifibrotic effects by inhibiting the transforming
growth factor beta (TGF-β1)-induced fibrogenic property
of HSCs via transcriptional coactivator p300 [22]. TGF-β1
is the most characterized of the fibrotic cytokines and has
been found to be increased in HCV-HIV co-infected
patients [23]. It has also been proposed that the anticancer
effects of metformin in HCV-infected patients may also be
via AMPK and the inhibition of mammalian target of rapa-
mycin (mTOR), which in turn regulates cell cycle progres-
sion and cell growth [24]. There are no studies to date that
have looked at the effect of metformin in preventing pro-
gression of liver fibrosis or accelerating regression fibrosis
in patients treated with HCV antiviral therapy.
Alpha-fetoprotein (AFP) is an oncofetal protein associ-
ated with hepatic malignancies and liver regeneration
[25, 26]. HCV core protein, inflammation, necrosis and
hepatocellular injury have all been suggested as causes for
elevated AFP levels in chronic HCV infection [25–28]. Al-
though type 2 diabetes and insulin resistance have been
identified as risk factors for the progression of liver fibrosis
and development of hepatocellular carcinoma the mechan-
ism by which this occurs is not clear [9, 11, 29, 30]. The re-
lationship between AFP and insulin resistance was recently
examined in a retrospective analysis of 300 HCV-infected
patients [31]. This study demonstrated that whole-body in-
sulin resistance and hepatic fibrosis correlated directly with
elevated levels of AFP lifestyle modification over a 3-month
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period correlated with improved insulin resistance and a re-
duction in AFP levels. This study draws attention to the
need for further prospective studies to understand the rela-
tionship between insulin resistance, AFP, hepatic fibrosis
and hepatocarcinogenesis. No studies have examined the
effect of metformin, an insulin sensitizer, on AFP levels.
While SVR is associated with improved liver out-
comes, the rate of liver fibrosis regression with SVR is
variable and predictors of regression are not well estab-
lished [32]. In addition, achieving SVR in patients with
cirrhosis does not necessarily prevent decompensation
or eliminate the risk of HCC. A better understanding of
the role insulin resistance and impaired glucose metab-
olism have on these outcomes in HCV patients who
achieve SVR are needed.
Identifying and targeting potentially modifiable risk fac-
tors such as IR may be of significant importance in pre-
venting progression of and promoting regression of liver
fibrosis, reducing mortality and improving outcomes for
HCV-HIV co-infected and HCV mono-infected patients.
Given the above body of evidence and the established
safety of metformin in HCV and HIV, we developed a
protocol to evaluate the effect of metformin on prevent-
ing progression or promoting regression of liver fibrosis,
rate of virologic cure (SVR) and other metabolic mea-
sures in HCV-HIV co-infected and HCV mono-infected




The use of metformin will slow the progression and pro-
mote regression of liver fibrosis in HCV-HIV co-infected
and HCV mono-infected patients with impaired insulin
sensitivity (defined as HOMA-insulin resistance > 2.0).
Objectives
The primary objective of this study will be to evaluate
the role of metformin in preventing progression and
promoting regression of liver fibrosis in HCV-HIV co-
infected and HCV mono-infected participants with IR
receiving antiviral HCV treatment as assessed by transi-
ent elastography (FibroScan®, Echosens, Paris, France).
As secondary objectives we will evaluate the effect
metformin has on virologic response rates based on SVR
(i.e. 12 weeks post HCV antiviral treatment and its effect
on the progression and regression of liver fibrosis using
aspartate aminotransferase (AST)-to-platelet ratio index
(APRI). We will additionally consider the effect of metfor-
min and lifestyle modification have on metabolic parame-
ters (fasting insulin, fasting glucose and fasting lipid levels),
inflammatory markers [interleukin 6 (IL-6), interleukin
8 (IL-8), tumor necrosis factor alpha (TNF-α), TGF-β,
C-reactive protein (CRP], anthropometric measurements
[weight, body mass index (BMI), waist circumference], AFP
levels, HCV viral status, human immunodeficiency virus
(HIV) viral status and liver enzymes. Patient acceptability of
metformin will be evaluated in arm 1 using a patient ac-
ceptability questionnaire. All participants will receive life-
style and dietary counselling at baseline and at 24-week
intervals. The effects of lifestyle modification will be evalu-
ated using dietary and physical activity questionnaires.
Study design and setting
This study is a prospective 48-week single-centre, random-
ized, open-label, controlled trial of HIV-HCV co-infected
and HCV mono-infected patients with IR (HOMA-IR ≥
2.0) who are planning to initiate HCV antiviral therapy.
Sixty (60) participants meeting eligibility criteria will
be randomized in a 1:1 ratio using variable block sizes to
either arm 1, metformin 2 g [1 g twice a day (BID)] plus
lifestyle, or to arm 2, lifestyle alone (the control arm).
Randomization will be stratified according to HIV status
and according to stage of liver fibrosis (F0–2 vs. F3–4)
and will be conducted utilizing a web-based randomization
system. The allocations will be generated by a statistician
unassociated with the study using the SAS statistical pro-
gram (SAS Institute, Inc., Cary, NC, USA) and uploaded
into the randomization system. A log of all transactions
including date and time of randomization, stratum and
treatment allocation will be recorded. The randomization
system will be accessed by the study coordinator at the
study site when they have identified consenting eligible par-
ticipants ready to be randomized.
Arm 1 (Metformin group) will receive metformin and
lifestyle treatment during a 12-week period prior to
starting HCV therapy (week 0–12), during the 12-week
treatment phase (week 12–24) and 24 weeks post HCV
treatment (week 24–48). Participants who require >
12 weeks of HCV treatment will be excluded. If initiation
of HCV treatment is delayed beyond 12 weeks, participants
will continue on metformin during this time period and will
receive less metformin post HCV treatment. Arm 2 (Con-
trol group) will receive lifestyle treatment alone during a
12-week period prior to starting HCV therapy (week 0–12),
during the 12-week treatment phase (week 12–24) and
24 weeks post HCV treatment (week 24–48). A detailed
study flow chart is depicted in Fig. 1.
Selection of participants
Participants will be recruited from The Ottawa Hospital
Viral Hepatitis Clinic. Study recruitment will begin in
July 2016. All adult patients between the ages of 18 and
79 years of age, who have provided informed consent,
have documented history of chronic HCV RNA infection
with evidence of fibrosis on FibroScan® > 8.0 kilopascals
(kPa) or liver biopsy score > 2 (Batts-Ludwig System [33]
within 2 years, insulin resistance as determined by a
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HOMA-IR of > 2.0 at screening and intend to start an
8–12 week interferon (IFN)-free HCV antiviral therapy.
If participants are HIV-infected and not on HIV antiviral
therapy, they will require a CD4 count of at least 200 to
be included in the study.
Individuals will be excluded from the study if they are:
pregnant, suspected to be pregnant, planning to become
pregnant or breastfeeding, have a chronic HBV infec-
tion, an HbA1c > 8.0 %, are using immune-suppressing
medications, have an active malignancy, are currently
or previously treated with metformin or other oral diabetes
medications or insulin, have a history of pre-existing
diabetes (type 1, type 2 or gestational diabetes), clinical
evidence of decompensated cirrhosis (ascites, esophageal
varices, hepatic encephalopathy, hepatocellular carcinoma),
renal impairment [serum creatinine levels > = 136 umol/L
(males), > = 124 umol/L (females)], history of congestive
heart failure requiring pharmacologic therapy, Wilson’s
disease, alpha-1 antitrypsin, hemochromatosis, biliary cir-
rhosis, alcohol consumption > 50 g/day on average, partici-
pation in other clinical investigations during the study, or a
history of lactic acidosis irrespective of precipitating factors.
Active illicit drug use (IDU) and stable health illness
will not be exclusionary assuming it is unlikely to com-
promise study adherence to protocol and study drug. In
HIV-infected participants, HIV antiretroviral use and
suppressed HIV viral load will not be required for
participation.
Informed consent and patient confidentiality
All participants will be given detailed oral and written infor-
mation about the trial. Consent forms describing in detail
Randomization: 1:1 Stratified based on HIV status and stage of liver fibrosis
Arm 1: Metformin 2 g (1 g bid)* + Lifestyle modification
N=30
12 weeks pre HCV treatment (weeks 0-12)
*(or highest tolerated dose)
Arm 2: Lifestyle modification (Control)
N=30
12 weeks pre HCV treatment (weeks 0-12)
Primary Outcome:
Progression/regression of liver fibrosis from baseline to start of HCV therapy 
(week 12), during treatment (week 12-24) and post HCV treatment (week 24 to
48) as measured by FibroScan® Score (kPa)
Eligible HCV-HIV co-infected and HCV mono-
infected participants with IR who are initiating 
HCV antiviral therapy (N=60)
Assessments at 0, 4, 8, 12, 16, 24, 36, 48 
weeks
Arm 1: Metformin 2 g (1 g bid)* + Lifestyle modification
+ HCV DAA Treatment (weeks 12-24)
*(or highest tolerated dose)
Arm 1: Metformin 2 g (1 g bid)* + Lifestyle 
modification
24 weeks post treatment (weeks 24-48)
*(or highest tolerated dose)
Arm 2: Lifestyle modification (Control) 
+ HCV DAA Treatment (weeks 12 to 24)
Arm 2: Lifestyle modification (Control)
N=30
24 weeks post treatment (weeks 24-48)
Fig. 1 Flow diagram of study processes. Sixty participants meeting eligibility criteria will be randomized in a 1:1 ratio using variable block sizes to
either arm 1, metformin 2 g (1 g BID) plus lifestyle (Metformin group), or to arm 2, lifestyle alone (Control group). Abbreviations: HCV hepatitis, HIV
human immunodeficiency virus, IR insulin resistance, BID twice daily, DAA direct-acting antiviral therapy, kPa kilopascals
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the study medication/intervention(s), study procedures
and risks will be given to each participant and written
documentation of informed consent is required prior
to starting study medication/intervention. Participants
may withdraw consent at any time during the course
of the trial.
All participant-related information including clinical
records, laboratory specimens, evaluation forms, reports,
will be kept strictly confidential. All records will be kept
in a secure, locked location and only research staff will
have access to the records. Participants will be identified
only by means of a coded number specific to each par-
ticipant and the site’s alphabetic letter code. All computer-
ized databases will identify participants by numeric and
alphabetic codes only, and will be password protected.
Metformin dosing
Arm 1 participants will be provided with the following
recommended dose adjustments and advised to increase
the dose accordingly: week 1: 500 mg once daily (QD);
week 2: 500 mg BID; week 3: 500 mg three times daily
(TID); week 4: 1 g BID or 500 mg QD. Participants will
also be encouraged to administer their study treatment
with food whenever possible to minimize the gastric intol-
erances. If participants are unable to tolerate an increase
in dose, they will continue on the last dose tolerated.
Metformin dosing will additionally be based on renal
function and dosed as follows:
 if creatinine clearance (CrCl) 30–60 mL/min,
metformin will be reduced to 50 % of the dose or
500 mg BID
 if CrCl < 30 mL/min, metformin will be stopped.
The potential side effects associated with metformin
will be reviewed with each participant.
Lifestyle modification intervention
Participants in both treatment arms will be given counsel-
ling on lifestyle and dietary modifications that may help to
prevent progression of liver fibrosis. Participants will be
given instructions on recommended types and duration of
physical activity as per Canadian Diabetes Association
practice guidelines. They will be encouraged to aim for
150 minutes of moderate to vigorous aerobic exercise
and two to three sessions of resistance training each
week. They will additionally be provided with tips on
how to become more active.
Participants will further be provided with recommenda-
tions for dietary modifications and tips for healthy eating
as provided by the Canadian Diabetes Association practice
guidelines. Recommended limits for alcohol consumption
will be reviewed. The educational sessions will be repeated
during 6-month follow-up visits.
Primary outcome
As the primary outcome we will evaluate the change in
FibroScan® score (kPa) from baseline to week 12 (start of
HCV treatment), the end of HCV treatment (week 24)
and 24 weeks post HCV treatment (week 48) (Table 1).
Secondary outcomes
The following will be evaluated as secondary outcomes:
(i) virological response rates (SVR 12 weeks post HCV anti-
viral therapy) will be compared between treatment groups;
(ii) the change in APRI measurements from baseline to
start of HCV treatment, to the end of HCV treatment
(week 24) and 24 weeks post HCV treatment (week 48) will
be compared between treatment groups; (iii) changes in
glucose metabolism (HOMA-IR, fasting insulin, glucose
levels) from baseline to 4, 8, 12, 24, 36 and 48 weeks; (iv)
changes in lipid levels [total cholesterol, low-density lipo-
protein cholesterol (LDL-c), high-density lipoprotein chol-
esterol (HDL-c), triglycerides] from baseline to 0, 12, and
36 and 48 weeks; (v) changes in anthropometric measures
(waist circumference, body weight and BMI) from baseline
to 0, 4, 8, 12, 24, 36 and 48 weeks; (vi) changes in liver-
related inflammatory markers by (IL-6, IL-8, TNF-α, TGF-
β, C-reactive protein (CRP)) from baseline to 0, 4, 8, 12, 24
and 36 weeks; (vii) changes in AFP levels from baseline to
0, 12, 24, 36 and 48 weeks; (viii) participant acceptability to
study medication dosing will be assessed (in arm 1 only) at
weeks 8, 24, and 48 weeks by questionnaire. Changes in
scores from week 8 to end of study will be evaluated; (ix)
changes in diet and physical exercise parameters from base-
line to 24 and 48 weeks using dietary and physical activity
questionnaires (Table 1).
Safety assessments
Metformin has been studied in both HCV and HIV
mono-infected patients with no increase in adverse
events (AE) [18, 34]. Metformin does have the potential
risk of lactic acidosis. A reduced dose (50 % of maximal
dose) is used for patients with a CrCl < 60 mL/min. It is
not recommended for use in patients with a creatinine
clearance of < 30 mL/min. Patients will be cautioned
against excessive alcohol intake, either acute or chronic
when taking metformin, since alcohol intake potentiates
the effect of metformin on lactate metabolism [35, 36].
A Data and Safety Monitoring Committee (DSMC)
will be implemented to safeguard participant safety. All
members will be independent from the study investigators.
This committee will conduct regularly scheduled meetings
to review the study progress including recruitment and
conduct, and will identify any potential safety signals in the
study population.
At each contact with the participant, information re-
garding adverse events (AEs) will be elicited by
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appropriate questioning and examinations. Any AE that
occurs between the time that the participant is random-
ized and the time that s/he departs the study at the end
of the final follow-up visit (or at the time of early
withdrawal of the participant from the study for any rea-
son) is to be recorded. Participants will also be moni-
tored during the 48-week study period for serious
adverse events (SAEs). If an SAE is ongoing at the time a
Table 1 Schedule of events and data collection
Visit window +/- 2 days
Weeks -4 (Screen) 0 (Baseline) 4 8 12 16 24 36 48
Informed consent X
Medical history X
Inclusion/exclusion criteria X X
Drug, alcohol and smoking history X
Pregnancy testa X Xa
Medication review X X X X X X X X X
FibroScan®b X X X X X X
Physical examinationc and vital signs X Xc Xc Xc Xc Xc Xc Xc Xc
Hepatitis B serologyd X
HCV RNA viral loade Xe X X X X X X X X
HCV genotyped X
HIV viral loadd,e (as per SOC) Xe X X X X X
CD4 counte (as per SOC) X5 X X X X X
Hematologyf and chemistryg X X X X X X X X X
HbA1c X X X X X X
Fasting insulin and glucose X X X X X X X X X
Fasting lipidsh X X X X X
Inflammatory markers/research blood X X X X X X X X
TSH X X X X
AFP levels X X X X X
2-hr OGTT X X
Adverse events X X X X X X X
Anthropometric measuresi Xi X X X X X
Counselling on lifestyle modification X X X
Block food frequency questionnaire X X X
International physical activity questionnaire X X X
Audit-C and illicit drug use questionnaires X X X X X
TSQM for patient acceptability (arm 1) X X X
Study drug accountability/dispensation (arm 1) X X X X X X X
Birth control review X X X X X X X X
HCV hepatitis C, HIV human immunodeficiency virus, HbA1c glycated hemoglobin, TSH thyroid-stimulating hormone, AFP alpha-fetoprotein, OGTT oral glucose
tolerance test, TSQM Treatment Satisfaction Questionnaire for Medication
aIf randomization occurs > = 4 weeks from last pregnancy test, perform pregnancy test at baseline
bFibroScan® can be done at screening if necessary for inclusion; baseline test can be done on different day than rest of visit if necessary (within 4 weeks of
baseline). FibroScan® window can be +/− 7 days of the week 12 visit, +/− 21 days of week 24 and 36 visits, and up to 21 days before the week 48 visit
cTargeted physical exam: vitals, cardiac, respiratory and abdominal exams; exam as pertinent to patient complaints
dTests to be done if not already in participant medical records [hepatitis B (HBV) needs to be within 6 months of screening visit; HIV needs to be within 1 month
of screening]
eIf results available within 1 month of screening visit, no need to retest
fHematology: complete blood count (CBC) with differential, platelets, international normalized ratio (INR)
gChemistry: electrolytes, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), lipase, albumin, direct bilirubin, lactate,
creatinine, estimated glomerular filtration rate (eGFR)
hLipids: total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides
iAnthropometric measures: height, weight, body mass index (BMI), waist circumference, hip circumference, waist-to-hip ratio. At screening, only height and
weight documented
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participant discontinues/completes the trial, the SAE will
be followed until the investigator agrees that the event is
satisfactorily resolved, becomes chronic, or that no further
follow-up is required (Table 1).
Study treatment adherence
The following criteria will be used to define compliance
during this study:
1. Adherence with study treatment will be assessed
based on participant-provided information and tablet
count, i.e., drug accountability, during follow-up visits.
Non-adherence will be considered for participants
who have an average daily intake of less than 80 % of
their maximum tolerated dose.
2. Attend baseline visit and all follow-up visits.
3. Adherence with HIV antiretroviral therapy (ART)
(if applicable) and HCV antiviral therapy will be
documented as standard of care.
Sample size calculation
To date there have been no studies that have investi-
gated the benefits of improved IR in the HIV-HCV co-
infected population or in HCV mono-infected patients.
Studies that have investigated the effects of HCV anti-
viral therapy on FibroScan® score reported a 32 % reduc-
tion in mean score (10.6 +/- 4.8 kPa) compared with
baseline in patients that obtained a treatment response
[37]. Based on these study results, a sample size of 24
participants in each group would provide approximately
80 % power to detect a 4 kPa difference between the two
treatment arms assuming a similar standard deviation.
We anticipate a 20 % loss to follow-up, so an additional
six participants will be randomized per group to account
for loss to follow-up and to allow secondary outcome
analyses. Using regression of the final measurement on
the initial measurement will likely improve the power
relative to using simple difference scores.
All analyses will be based on intention-to-treat basis
and per protocol analysis. Intention-to-treat popula-
tion will be defined as the set of all patients
randomized.
Statistical analysis
As the primary outcome of this study, the influence of
metformin on preventing and promoting regression of
liver fibrosis in HCV antiviral treatment recipients will
be assessed by transient elastography. The change in
transient elastography scores (kPa) at week 48 (24 weeks
post HCV therapy) between groups will be assessed
using linear regression adjusted for baseline score. We
will also compare the trend on fibrosis progression over
the course of the study (12, 24, 36 and 48 weeks) between
groups using mixed-effects regression analysis. All analyses
will be based on intention-to-treat basis. A sensitivity ana-
lysis of the change at 48 weeks will be conducted using
multiple imputations to include those participants who do
not have 48-week follow-up scores.
The same set of analyses based on a per protocol basis
will also be performed. For the analysis, which examines
the outcome longitudinally, participants who terminated
the assigned treatment prematurely will be censored at
the time that they went off treatment.
Secondary outcome measures include: virological re-
sponse rates, changes from baseline to week 48 in indirect
measures of liver fibrosis (APRI), inflammatory markers,
metabolic measures, anthropometric measurements, HCV
and HIV viral loads, AFP levels and liver function. Linear
regression adjusted for baseline score will be used to com-
pare the outcome at week 48 between groups. Mixed-
effects regression analysis will also be used to compare the
trend over time between groups.
To account for potential confounding factors (i.e., HCV/
HIV viral status, alcohol consumption, IR, BMI) associated
with changes in liver fibrosis, a sensitivity analysis based
on multivariate regression analysis will be performed.
Patient acceptability of daily long-term study treatment
use will be evaluated (in arm 1 only) using the Treatment
Satisfaction Questionnaire for Medication. Patient accept-
ability will be assessed based on change in median score
from week 8 (first administration of questionnaire) to
week 24 and week 48. Descriptive statistics will be used to
summarize the data.
Baseline characteristics will be expressed as mean and
standard deviation (SD) for continuous variables and per-
centages for categorical variables. Baseline variables to be
considered include: age, gender, ethnicity, HCV genotype
and viral load, HIV viral load and CD4 count (as per SOC),
HbA1c, HOMA-IR, FibroScan® scores, smoking history, al-
cohol consumption, and illicit drug use.
Lifestyle modification will be evaluated through changes
in physical activity (changes in median MET/week, percent-
age change in participants classified as low, medium and
high level of activity) and dietary changes (change in me-
dian daily caloric intake, daily consumption of fat, protein,
carbohydrates and micro/macro nutrients). Linear regres-
sion adjusted for baseline score will be used to compare the
outcome at week 48 between groups. Mixed-effects regres-
sion analysis will also be used to compare the trend over
time between groups.
Data will be collected on liver-related complications
(progression of liver fibrosis stage, HCC, transplantation)
and mortality. We anticipate that the event rate will be
low given the small sample size and short duration of
follow-up.
Subgroup analyses will be conducted based on SVR to
compare the effect virological response influences liver fi-
brosis and the benefit of metformin in reducing progression
Doyle et al. Trials  (2016) 17:331 Page 7 of 10
of fibrosis. Subgroup analyses will also be conducted based
on HIV status to compare the influence of HIV infection
on progression of liver fibrosis and benefit of metformin in
reducing the progression of fibrosis.
Subgroup analyses based on metformin doses (full
dose versus not) in the metformin group and weight loss
in patients in both treatment arms will also be con-
ducted. These additional analyses will be useful in deter-
mining if lower doses can achieve the same benefit and
the impact that potential weight loss associated with this
medication may have on steatosis and improving liver
outcomes respectively.
Subgroup analyses will also be conducted based on
end of study HOMA-IR score (<2 vs. > 2) to evaluate if
the benefits of metformin are dependent or independent
of the insulin-sensitizing effects of this treatment.
As a sensitivity analysis, we will also consider using
multiple imputation techniques to impute missing data
for the primary outcome at 48 weeks. Linear regression
adjusted for baseline score will then be used to compare
the groups.
When half (n = 30) of the participants have completed
their 48-week visit, an interim analysis of efficacy will be
conducted. The same technique and analytic strategy
will be used to analyze the primary end point, transient
elastography score (kPa) at 48 weeks. An intention-to-
treat approach will be taken, linear regression adjusting
for baseline score, and missing imputations to account
for missing data will be used. The O’Brien-Fleming ap-
proach using the Lan-DeMets alpha spending function
will be used, so that the criterion for statistical signifi-
cance at the first analysis will be 0.005 and the criterion
at the final analysis will be 0.048 to maintain 80 % power
overall. This analysis will be supplemented by a mixed-
effects regression model examining the outcome at all
time points for all patients available, and adjusting for
baseline values.
Early termination
The criteria for premature discontinuation of further
study medication for an individual participant in arm 1
are as follows: treatment-related toxicity, requirement
for prohibited concomitant medications, clinical reasons
believed to be life-threatening by the physician, even if
not addressed in the toxicity section of the protocol.
The participant will continue to be followed with the
participant’s permission if the study medication is prema-
turely discontinued. If the participant discontinues study
medication between scheduled visits, the investigator may
request that the participant visit the clinic as soon as
possible for lab and safety assessments and to return
the study medication for accountability purposes. There
will be no changes to the follow-up visit schedule,
except no study medication will be administered. If the
participant chooses not to remain in the study, then the
participant will be withdrawn from the study and par-
ticipant will be asked to come in for an early termin-
ation visit.
The criteria for permanent withdrawal from the study
for an individual participant are as follows:
loss to follow-up, pregnancy or suspected pregnancy,
HCV treatment required for >12 weeks, request of the
participant to withdraw from the trial, any clinical AE,
laboratory abnormality, intercurrent illness, other med-
ical condition or situation occurs such that continued
participation in the study would not be in the best inter-
est of the participant, the participant is judged by the
investigator to be at significant risk of failing to comply
with the provisions of the protocol as to cause harm to
self or seriously interfere with the validity of the trial results,
progression of diabetes requiring additional diabetes medi-
cation (i.e. oral diabetes medications or insulin therapy).
In the event that the participant is withdrawn from the
study due to an AE, this must be recorded on the case
report form (CRF). The subject should be followed and
treated by the investigator until the abnormal parameter
or symptom has resolved or stabilized.
Trial registration and dissemination
This study has been registered with ClinicalTrials.gov
(Identifier Number NCT02306070, https://clinicaltrials.
gov/ct2/show/NCT02306070). A SPIRIT checklist is pro-
vided as an additional file (see Additional file 1). The
findings of this trial will be submitted to a peer-reviewed
journal and abstracts will be presented at relevant national
and international conferences.
Discussion
HCV antiviral therapy has evolved rapidly in recent years
and access to these medications has improved. While
SVR is associated with improved liver outcomes, the rate
of liver fibrosis regression with SVR is variable and predic-
tors of regression are not well established [32]. In addition,
achieving SVR in patients with cirrhosis does not neces-
sarily prevent decompensation or eliminate the risk of
HCC. A better understanding of the role insulin resistance
and impaired glucose metabolism have on these outcomes
in HCV patients who achieve SVR are needed.
Identifying and targeting potentially modifiable risk
factors such as IR and T2DM may be of significant im-
portance in preventing progression of and promoting
regression of liver fibrosis, reducing mortality and im-
proving outcomes for HCV-HIV co-infected and HCV
mono-infected patients.
This pilot study will be the first to evaluate the role of
metformin on liver fibrosis in HCV-HIV co-infected and
HCV mono-infected patients with IR receiving DAA
HCV treatment. If metformin is effective in reducing liver
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fibrosis in this patient population, this will represent a well-
tolerated, easy-to-administer, inexpensive therapy that will
protect against negative HCV outcomes. This study will
also be an opportunity to evaluate the impact of insulin re-
sistance and hyperglycemia on viral clearance in HCV-
infected patients treated with interferon-free regimens. In
addition, the study will further explore the relation-
ship between HCV, insulin resistance and AFP levels.
This knowledge will inform patient care, translate into
improved therapeutic outcomes for liver and meta-
bolic diseases, and guide further innovative research
in this area.
Trial status
Recruitment for this study will begin in July 2016.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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